Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Looks To Longer Revlimid Duration In MM To Expand Revenue

Executive Summary

At ASH, Celgene detailed the results of its MM-020 study for continuous use of Revlimid in newly diagnosed multiple myeloma patients. That’s just one of several treatment strategies that could significantly increase patient time on the drug – and Revlimid revenues.

Advertisement

Related Content

For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon
Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055802

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel